Jefferies Maintains Buy on Novavax, Maintains $31 Price Target
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Roger Song has reiterated a Buy rating for Novavax (NASDAQ:NVAX) and maintained a price target of $31.
October 02, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jefferies analyst Roger Song has reiterated a Buy rating for Novavax and maintained a price target of $31, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a specific price target by a reputable analyst can positively influence investor sentiment and potentially lead to a short-term increase in the stock price. The $31 price target suggests an upside potential from current levels.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100